Table 2.
Tabular presentation for PROBAST results*.
| ROB | Applicability | Overall | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | Outcome | Participants | Predictors | Outcomes | Analysis | Participants | Predictors | Outcomes | Bias | Applicability |
| Polilli E 2022 (29) | Hospitalization and mortality | - | + | - | - | + | + | - | - | - |
| Wanyan T 2022 (30) | Mortality | - | + | - | - | + | - | - | - | - |
| Lazzarini N 2022 (31) | Hospitalization | + | + | - | - | + | - | - | - | - |
| Wang A 2022 (32) | Hospitalization | + | + | - | - | + | - | - | - | - |
| Vezzoli M 2022 (33) | Mortality | + | + | - | + | + | - | - | - | - |
| Ali S 2022 (34) | Mortality | - | - | - | + | + | - | - | - | - |
| Zarei J 2022 (35) | Mortality | + | + | + | + | + | + | + | ? | + |
| Baik SM 2022 (36) | Mortality | - | - | - | - | + | - | - | - | - |
| Shanbehzadeh M 2022 (37) | Hospitalization | + | + | - | - | + | - | - | - | - |
| Song W 2022 (38) | Hospitalization | + | + | - | - | + | + | - | - | - |
| Willette AA 2022 (39) | Hospitalization | + | + | - | - | + | + | - | - | - |
| Wan TK 2022 (40) | Mortality | ? | + | - | - | + | ? | - | - | - |
| Park MS 2022 (41) | Mortality | - | + | ? | - | - | ? | ? | ? | + |
| Jakob CEM 2022 (42) | Hospitalization | ? | + | ? | - | + | + | ? | - | - |
| Hernández-Pereira E 2022 (43) | Hospitalization | ? | - | - | - | ? | - | - | - | - |
| Gutierrez JM 2021 (44) | Hospitalization | + | + | + | - | + | ? | + | ? | - |
| Guan X 2021 (45) | Mortality | - | + | - | - | ? | - | - | - | - |
| Feng C 2021 (46) | Mortality | + | - | ? | - | + | - | ? | - | - |
| Kasturi SN 2021 (47) | Hospitalization | + | + | + | - | ? | ? | + | + | - |
| Murri R 2021 (48) | Mortality | ? | - | - | - | + | - | - | - | - |
| Tabatabaie M 2021 (49) | Mortality | ? | - | - | - | + | - | - | - | - |
| Moulaei K 2021 (50) | Mortality | ? | - | - | - | + | - | - | - | - |
| Migriño JR Jr 2021 (51) | Mortality | - | - | - | - | - | - | - | - | - |
| Banoei MM 2021 (52) | Mortality | ? | + | + | - | + | + | + | - | - |
| Dabbah MA 2021 (53) | Mortality | + | ? | ? | - | + | ? | - | - | - |
| De Souza FSH 2021 (54) | Mortality | + | - | ? | - | + | - | - | - | - |
| Ottenhoff MC 2021 (55) | Mortality | + | + | ? | - | + | - | - | ? | - |
| Mahdavi M 2021 (56) | Mortality | + | - | + | - | + | - | - | - | - |
| Jamshidi E 2021 (57) | Mortality | - | + | ? | - | - | - | - | - | - |
| Snider B 2021 (58) | Mortality | - | + | ? | - | - | - | - | - | - |
| Halasz G 2021 (59) | Mortality | + | + | ? | - | + | - | - | - | - |
| Karthikeyan A 2021 (60) | Mortality | + | - | ? | - | + | - | - | - | - |
| Tezza F 2021 (61) | Mortality | ? | - | ? | - | + | - | - | - | - |
| Pourhomayoun M 2021 (62) | Mortality | ? | + | ? | + | + | ? | ? | ? | ? |
| Jimenez-Solem E 2021 (63) | Hospitalization and mortality | ? | ? | ? | ? | ? | - | - | ? | - |
| Gao Y 2020 (64) | Mortality | ? | ? | ? | - | ? | - | - | - | - |
| Wang T 2020 (65) | Mortality | + | ? | ? | - | - | - | - | - | - |
| An C 2020 (66) | Mortality | + | ? | ? | + | ? | ? | - | ? | - |
| Vaid A 2020 (67) | Hospitalization and mortality | + | ? | ? | ? | - | - | - | ? | - |
PROBAST, Prediction model Risk Of Bias ASsessment Tool; ROB, risk of bias.
*+ indicates low ROB/low concern regarding applicability; – indicates high ROB/high concern regarding applicability; and ? indicates unclear ROB/unclear concern regarding applicability.